LOS ANGELES, January 8, 2007 – Kythera Biopharmaceuticals, Inc. (“Kythera”)
announced today that it has commenced the Company’s first human clinical trial, a
Phase I/II study of ATX-101 for the reduction of localized fat deposits.
“This important milestone not only substantiates our belief in the potential of ATX-101,
but also validates our scientifically and medically rigorous approach to developing
prescription therapeutics in aesthetic and restorative dermatology,” said Keith Leonard,
Kythera’s President and CEO. “We hope ATX-101 will prove to be a new treatment
option for patients, and we are truly excited about the potential of ATX-101 in all
possible medical and aesthetic applications.”
ATX-101 is initially being investigated for the treatment of superficial lipomas, a type of
benign musculoskeletal fatty tumor that may occur in up to 2% of the population.
Lipomas are generally found on the torso, shoulder, arms and legs, and, while generally
asymptomatic, can cause local pain, tenderness or nerve compression. Individuals
seek to have their lipomas removed in order to reduce pain, for aesthetic reasons, or
both.
This ATX-101 clinical trial is being conducted in the United States and is intended to
identify the pharmacokinetics, safety and potential efficacy of ATX-101 in the treatment
of superficial lipomas. The Phase I/II randomized, double blind, placebo-controlled
study is the first of several planned trials to investigate the medical and aesthetic uses
of ATX-101. Kythera licensed the compound from Los Angeles Biomedical Institute at
Harbor-UCLA Medical Center.
“Until now, standard lipoma treatment has been surgical excision, which many patients
opt not to undergo due to the invasiveness and potential for scarring,” said Jay
Birnbaum, Kythera’s Chief Medical Officer. “We are hopeful that treatment with ATX-
101 can significantly reduce the size of, or eliminate, lipomas and thereby provide an
effective non-surgical, minimally invasive treatment option for patients.”
Recent Comments